The Fall 2026 Prime Therapeutics Report delivers a comprehensive look at the evolving oncology landscape—from rising cancer rates in younger populations to the expanding role of radiopharmaceuticals and cellular therapies.  

Inside this issue:  

• Oncology accelerated approval update: Traditional approvals and withdrawals 
• Pancreatic cancer: persistent unmet need and the promise of RAS-targeted therapy 
• Breast cancer: Treatment landscape and pipeline 
• The next phase of CAR T: Expanding indications and emerging frontiers 
• Rising cancer drug costs: Management in the era of AI 
• Subcutaneous oncology biologics: What utilization and allowed amount data reveal 
• Pipeline 

Whether you’re a managed care executive, clinician or pharmacy leader, this report offers practical insights to help evaluate emerging therapies, prepare for market changes and support informed coverage, access and management decisions.  

Read the report

Subscribe for future issues